Clinical trial · Interventional
Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma
New Method of Treatment for Thoracoscopy or Bronchoscopy by Suspension of Fine Powder of Talcum and Afatinib is Used in Patients With Positive Mutation of EGFR in Non-Small Cell Lung Carcinoma (NSCLC)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In non-small cell lung cancer and metastases in the pleural cavity, pathological effusion is formed. Currently, the most common and effective method of obliteration of the pleural cavity is pleurodesis with talcum powder. Talc, when it surface of the pleura, causes chemical inflammation that leads to the soldering of the lungs and chest wall. As a result, the liquid ceases to accumulate. The addition of a therapeutic dose of afatinib to talc not only blocks effusion into the pleural cavity, but also reduces tumor and metastatic processes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Afatinib | Drug | Afatinib | ALIAS |
| Talcum powder | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Talcum powder & Afatinib
- description
- Talcum powder 4 g + Afatinib 0,4 g. Is entered once
- interventionNames
- Drug: Afatinib
- Drug: Talcum powder
Primary outcomes (1)
- measure
- The effectiveness of the procedure of dry pleurodesis through a thoracoscope
- timeFrame
- up to 90 days
- description
- Evaluation of the effectiveness of the dry pleurodesis procedure in combination with talc and afatinib with the introduction of a powder suspension through a thoracoscope. The assessment is performed by CT (computed tomography) of each participant twice: 30 days from the day of the procedure and 90 days later.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 21 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Non-small cell lung cancer with positive mutation of EGFR verified * Malignant pleural effusion * Recurrent pleural effusion * Complete lung expansion (\> 80%) after puncture emptying confirmed by chest radiography. * Karnofsky index \> 50 * Agreed to participate in the study and sign an Informed Consent Exclusion Criteria: * Radiotherapy not earlier than 3 months before the pleurodesis procedure * Previous surgeries on the same hemitorace * Thrombocytopenia or coagulation disorders * Trapped lung syndrome * Patients with estimated life expectancy \< 4-8 weeks * Pleural or active systemic infection
References
Publications (0)
Data not yet available